NASDAQ:NTLA   Intellia Therapeutics, Inc.
Genome editor Intellia Therapeutics poised for new highs after pulling back from high-volume charge at this mark Wednesday. Strong sales, less than desirable earnings and cash flow, but perhaps the momentum is gaining there.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。